argenx: Vyvgart Is Taking Off (Rating Upgrade)

Impact · against what's priced in

The Q2 results confirm strong operational leverage and cash generation for argenx, providing a solid foundation for its $50B+ valuation. The potential for empasiprubart in MMN serves as a forward-looking catalyst to drive the stock beyond current commercial success.

ARGX+0.60

No priced-in read yet

In context

Surging profitability, $3.6B in cash, and the prospect of empasiprubart in MMN provide a combination of immediate financial strength and future clinical catalysts.

Read from the article alone

• cash flow▲13%
• earnings
• pharmaceuticals
• biotech
• ARGX
• autoimmune
• pipeline

Top 1 mover · tap to explore